HyQvia + Subcuvia

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Multifocal Motor Neuropathy

Conditions

Multifocal Motor Neuropathy

Trial Timeline

Jun 1, 2016 → May 1, 2018

NCT ID

NCT02556437

About HyQvia + Subcuvia

HyQvia + Subcuvia is a phase 2 stage product being developed by Baxter for Multifocal Motor Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02556437. Target conditions include Multifocal Motor Neuropathy.

What happened to similar drugs?

0 of 1 similar drugs in Multifocal Motor Neuropathy were approved

Approved (0) Terminated (0) Active (1)

🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02556437	Phase 2	Completed	Jun 1, 2016	May 1, 2018	Multifocal Motor Neuropathy

Competing Products

7 competing products in Multifocal Motor Neuropathy

See all competitors

Product	Company	Stage	Hype Score
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	35
Vivaglobin	CSL	Phase 2	35
ARGX-117	Argenx	Phase 2	36
Empasiprubart + IVIG (Intravenous Immunoglobulin)	Argenx	Phase 3	44
ARGX-117	Argenx	Phase 2	32
mefloquine	Biogen	Phase 1/2	21
Tysabri	Biogen	Pre-clinical	23